Ken Griffin Kymera Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $60,320 - $104,800	2,000 Added 8.85%	24,600 $1.16 Million
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $304,470 - $402,084	-10,200 Reduced 31.1%	22,600 $674,000
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $380,140 - $723,262	16,600 Added 102.47%	32,800 $1.32 Million
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $7,679 - $18,788	700 Added 4.52%	16,200 $412,000
Q3 2023 Nov 14, 2023	SELL	$13.9 - $23.88 $140,390 - $241,188	-10,100 Reduced 39.45%	15,500 $215,000
Q2 2023 Aug 14, 2023	SELL	$22.4 - $34.92 $129,919 - $202,536	-5,800 Reduced 18.47%	25,600 $588,000
Q1 2023 May 15, 2023	SELL	$24.84 - $38.75 $1.69 Million - $2.64 Million	-68,100 Reduced 68.44%	31,400 $930,000
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $702,563 - $1.11 Million	35,900 Added 56.45%	99,500 $2.48 Million
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $2.14 Million - $3.5 Million	-102,200 Reduced 61.64%	63,600 $1.39 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.22B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.